A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Recruiting · NCT06969430 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT06969430 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Debiopharm International SA | 10 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Moffitt Cancer Center and Research Institute Hospital | Tampa | United States | 1 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 32 |
| START Midwest | Grand Rapids | United States | 79 |
| The Ohio Sate University | Columbus | United States | 1 |
| University of Chicago | Chicago | United States | 312 |